Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes

详细信息    查看全文

• 作者：Lulu Li ; Minli Zhang ; Fuxiang Su ; Yang Li ; Yali Shen…
• 关键词：Acute coronary syndrome ; Diabetes ; Statins ; Ezetimibe ; Combination therapy
• 刊名：Lipids in Health and Disease
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：14
• 期：1
• 全文大小：555 KB
• 参考文献：1. Goldfine Allison, B, Beckman Joshua, A (2008) Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation 117: pp. 1914-1917 CrossRef
  2. Haffner, SM, Lehto, S, R?nnemaa, T, Py?r?l?, K, Laakso, M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: pp. 229-234 CrossRef
  3. Delahoy, PJ, Magliano, DJ, Webb, K, Grobler, M, Liew, D (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 31: pp. 236-244 CrossRef
  4. Amsterdam, EA, Wenger, NK, Brindis, RG, Casey, DE, Ganiats, TG, Holmes, DR (2014) 2014 AHA/ACC Guideline for the Management of patients with non-ST-elevation acute coronary syndrome. J Am Coll Cardiol S0735-1097: pp. 06279-2
  5. Zhao, S, Wang, Y, Yiming, M, Yu, B, Ye, P, Yan, X (2014) Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS). Atherosclerosis 235: pp. 463-9 CrossRef
  6. Rocco Michael, BR (2012) Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 79: pp. 883-893 CrossRef
  HPS2-THRIVER randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: pp. 1279-91 CrossRef
  7. Neal Ryan, C, Jones Peter, H (2006) Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manage 2: pp. 31-8 CrossRef
  8. Mikhailidis, DP, Sibbring, GC, Ballantyne, CM, Davies, GM, Catapano, AL (2007) Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 23: pp. 2009-26 CrossRef
  9. Necati, D, Mustafa, Y, Ilgin, K (2007) The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30: pp. 230-5 CrossRef
  10. Nomura, M, Ishii, H, Kawakami, A, Kajinami, A, Yoshida, M (2009) Inhibition of hepatic Neiman-pick C1-Like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 297: pp. E1030-8 CrossRef
  Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 35: pp. 390-419
  11. He, J, Gu, D, Wu, X, Reynolds, K, Duan, X, Yao, C (2005) Major causes of death among men and women in China. N Engl J Med 353: pp. 1124-34 CrossRef
  12. Pedersen, TR, Faergeman, O, Kastelein, JJ, Olsson, AG, Tikkanen, MJ, Holme, I (2005) Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: pp. 2437-45 CrossRef
  13. Cannon, CP, Braunwald, E, McCabe, CH, Grayston, JT, Muhlestein, B, Giugliano, RP (2004) Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: pp. 1495-504 CrossRef
• 刊物主题：Lipidology; Medical Biochemistry;
• 出版者：BioMed Central
• ISSN：1476-511X

文摘

Background Dyslipidemia management situation in Chinese patients with high risk and very high risk has been demonstrated very low, despite the wide use of statins. The effects and safety of the combined treatment of ezetimibe (EZ) and statins in Chinese patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM) remain unknown. Methods Chinese Patients with ACS and T2DM were divided into the statins group (n--0) and the combination group of EZ and statins (n--4). In order to evaluate the clinical effects on lipids-lowering, systemic inflammation response and clinical safety, the follow-up of all patients was carried out at day 7th and 30th after treatment. Results The level of low-density lipoprotein cholesterol (LDL-C) in combination group and statins group was 1.87?±-.42 and 2.18?±-.58?mmol/L at day 7th, 1.51?±-.29 and 1.94?±-.49?mmol/L at day 30th, respectively. The control rates of LDL-C level in the combination group and the statins group were 77% and 45% at day 30th, respectively. There was no significant improvement on high-density lipoprotein cholesterol (HDL-C) level during follow-up. The triglyceride (TG) levels were significantly reduced in both groups, while no obvious difference was observed between two groups. No significant difference on serum high-sensitivity C-reactive protein (hs-CRP) level between two groups was observed. Moreover, we did not observe any significant correlation between serum lipids levels and serum hs-CRP level during follow-up. The liver dysfunction and muscle related side effects (MRSE), creatine kinase (CK) and myopathy were not observed in both groups. Conclusion Our study demonstrated that it is feasible to initiate combination therapy during acute phase for Chinese patients with ACS and T2DM, which can bring more significant effect on LDL-C-lowering and improve the control rate of LDL-C level with good safety.